W. Zhang, D. Yang, C. Harbison, S. Khambata-Ford, D. P. Malone, Y. Ning, P. O. Bohanes, A. Gerger, M. J. Labonte, L. Benhaim, A. B. El-Khoueiry, S. Iqbal, H. Lenz.
FCGR2A H131R and FCGR3A V158F polymorphism status in mCRC patients treated with single-agent cetuximab (IMCL 0144 and CA225045) or with second-line irinotecan plus cetuximab (EPIC): A pooled statistical analysis.
J Clin Oncol 29: 2011 (suppl; abstr e14025)2011; -2011 ASCO Annual Meeting; Jun 3-7, 2011; Chicago.
[Poster]